Transgenic mice carrying site-specific genome modifications (knockout, knock-in) are of vital importance for dissecting complex biological systems as well as for modeling human diseases and testing therapeutic strategies. Recent advances in the use of designer nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 system for site-specific genome engineering open the possibility to perform rapid targeted genome modification in virtually any laboratory species without the need to rely on embryonic stem (ES) cell technology. A genome editing experiment typically starts with identification of designer nuclease target sites within a gene of interest followed by construction of custom DNAbinding domains to direct nuclease activity to the investigator-defined genomic locus. Designer nuclease plasmids are in vitro transcribed to generate mRNA for microinjection of fertilized mouse oocytes. Here, we provide a protocol for achieving targeted genome modification by direct injection of TALEN mRNA into fertilized mouse oocytes.
Introduction
Mice are by far the most popular platform for generating transgenic animal models. The versatile toolbox for genetic engineering of the mouse embryo [1] [2] [3] has been recently extended by genome editing approaches based on designer nucleases such as zinc finger nucleases (ZFN) [4] [5] [6] , transcription activator-like effector nucleases (TALEN) 7, 8 , and the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPRassociated (Cas) 9 system 9 . ZFN and TALEN function as pairs of two custom-designed protein-based DNA-binding domains (arrays of zinc finger proteins and repeat-variable di-residues (RVDs), respectively) that are each coupled to the FokI endonuclease [10] [11] [12] . Conversely, the specificity of Cas9-mediated DNA cleavage is provided by transactivating CRISPR RNAs (crRNA and tracrRNA, which can also be combined into a single chimeric RNA molecule termed guide RNA) 11 that act in a complex with the CRISPR protein.
TALENs with a defined sequence of RVDs can be rapidly constructed by individual experimenters with a multitude of assembly strategies to choose from [13] [14] [15] [16] [17] . CRISPR/Cas9 promises even less labor-intensive generation of designer nucleases, however the specificity of guide RNA-DNA binding is still not completely resolved 18, 19 . Generation of custom ZFNs has so far been limited to specialized academic laboratories and to commercial suppliers such as Sangamo Biosciences and the Sigma CompoZr service.
In general, genome editing with designer nucleases aims at introducing double strand breaks (DSB) at defined genomic loci, which subsequently attract nonhomologous end joining (NHEJ) or homologous recombination (HR) DNA repair machineries 10, 12 . NHEJ-mediated repair of a DSB often results in the introduction of insertions and deletions in close proximity to the site of repair. Thus NHEJ repair can be exploited for knocking out the function of a target gene by introducing a frame-shift mutation within the genes protein-coding sequence 4, 7, 9 . Alternatively, defined addition or replacement of genetic information can be achieved by providing a DNA donor together with the designer nucleases. A DNA donor comprises investigator-designed DNA sequences flanked by regions of homology with the target locus, thus serving as a template for DSB repair by HR. Both plasmids 5, 6, 20 and single-stranded oligonucleotides 8, 9, 21 have been successfully used as donors. Neither NHEJ-nor HR-mediated genome editing require the introduction of a selectable marker into the genome of the mouse embryo, which makes these strategies particularly well suited for creating small alterations in the nucleotide sequence without disturbing the overall genetic architecture.
In this protocol we describe all essential procedures for genome editing in the mouse embryo using TALENs. These include 1) identification of a TALEN target site 22 , 2) construction of TALENs by golden gate cloning 13 , 3) in vitro synthesis of TALEN mRNA, 4) microinjection of TALEN mRNA into fertilized mouse oocytes, 5) surgical procedures for embryo transfer, and 6) analysis of TALEN-induced mutagenesis in founder animals. We focus on TALEN mRNA microinjection and screening of founders for NHEJ-induced insertions/deletions. For this purpose we have generated bifunctional TALEN constructs that allow both expression in mammalian cells when transfected as plasmids and in vitro synthesis of TALEN mRNA for microinjection into mouse embryos. These constructs comprise a truncated TALE backbone 23 fused to heterodimeric FokI under "Use a Preset Architecture" in order to predict target sites that can be targeted with the optimal spacer length (15-20 bp) and numbers of TALE RVDs (15) (16) (17) (18) (19) (20) for this TALEN architecture. 3. Choose "NN" under "G Substitute" (Guanosine-specific NH RVDs are also available but not yet extensively tested for TALEN assembly). 4. Optional: for other settings and options please follow the instructions on the website and the links provided there. 5. A textfile with potential target-sites is generated, which can be imported into a spreadsheet program for more convenient viewing. Select the TALEN pair(s) for Golden Gate assembly. 6. Optional: Sequence the genomic region of interest in the mouse strain that will be used for microinjection to detect possible single nucleotide polymorphisms (SNPs) that might not be accounted for in public databases and could potentially prevent nuclease binding. 7. Optional: Refer to Table 3 for additional designer nucleases-related online resources. 8. Most plasmids required for ZFN and TALEN construction can be obtained from Addgene:
http://www.addgene.org/special-collections/ Addgene IDs for the Golden Gate TALEN kit and mammalian TALEN expression constructs are provided in Table 2 . Alternatively, particular functional modules such as zinc finger domains can be ordered from a gene synthesis service provider.
Golden Gate TALEN Assembly
This section describes the assembly of TALENs using a protocol published by Cermak et al. 13 Full-length TALENs are constructed using two subsequent Golden Gate cloning steps (Figure 1 ). This approach allows the incorporation of any number of RVDs between 12 and 31 into the final expression constructs. The assembly protocol has been adapted to destination vectors designed for generating mRNAs ( Figure 1C ) that express highly active TALENs following oocyte microinjection. Please also refer to the online protocol of the Golden Gate TALEN kit for establishing and maintaining the plasmid library (http://www.addgene.org/TALeffector/goldengateV2/). . Add 1 µl 10 mM ATP and 1 µl Plasmid-Safe nuclease to each mix and incubate at 37 °C for 1 hr. This treatment will remove linear incomplete ligation products that could be cloned into the destination vectors by in vivo homologous recombination in transformed bacteria. 6. Transform E. coli with individual ligation reactions (electrocompetent or chemically competent E. coli that facilitate α-complementation such as XL1-Blue or DH5α can be used here and in subsequent transformations). 7. Plate bacteria on spectinomycin (50 µg/ml) plates with X-Gal and IPTG (40 µg/ml each) for blue/white colony selection.
1. By using colony PCR with primers pCR8_F1 and pCR8_R1 (See Table 1 for primer sequences) screen 1-3 white colonies from each plate. Correct pFUS-RVDs assemblies typically show a band corresponding to the combined length of all RVDs cloned (e.g. around 1.1 kb for 10 RVDs) and a "ladder" of smaller less prominent bands ( Figure 1B Use confirmed clones to start overnight culture (2-5 ml LB with 50 µg/ml spectinomycin).
Day 3 -Golden Gate Reaction #2 -RVD Arrays into TALEN Expression Vectors
1. Perform "minipreps" to isolate pFUS-RVD assemblies (depending on number of RVDs either pFUS_A and pFUS_B or pFUS_A30A, pFUS_A30B, and pFUS_B). 2. Optional: Sequence individual pFUS vectors using primers pCR8_F1, pCR8_R1 (see Table 1 
Day 4 -Confirmation of Correct TALEN Assembly
1. Screen 1-3 white colonies from each plate by colony PCR with primers TAL_F1 and TAL_R2 (see Table 1 for primer sequences).
Correctly assembled TALENs show a PCR product with a length corresponding to the total number of RVDs incorporated ( Figure 1D , this band is sometimes difficult to detect while the "ladder effect" represents a robust indicator of successful assembly Table 1 for primer sequences) to determine correct RVD assembly in full-length TALEN.
Nuclease mRNA Synthesis
1. Generation of DNA Template 1. Prepare high quality midi or maxipreps of pCAG-T7-TALEN plasmids for mRNA synthesis. 2. Linearize 10 µg of the TALEN or ZFN mRNA synthesis plasmid using a restriction enzyme that preferentially cleaves downstream and in close proximity to the nuclease STOP codon (for pCAG-T7-TALEN vectors use SacI). mRNA synthesis plasmids typically include a T7 or SP6 phage promoter upstream of the nuclease coding sequence. 3. Run 200-500 ng of digested plasmid on a 0.7-1% agarose gel to check for complete digestion. 4. Remove salts from plasmid digest by precipitating the DNA with 0.1 volume sodium acetate and 3 volumes ethanol for 1 hr at room temperature. Pellet the DNA by centrifugation at 14,000 x g or more for 10 min, wash the pellet with 200 µl 70% ethanol, spin for another 5 min, remove the ethanol, air dry the pellet and resuspend in an appropriate volume of RNAse-free water. Purification of the linearized plasmid is also possible using a column-based system, e.g. QIAquick PCR Purification Kit. 5. Determine the concentration of the linear template and use 1 µg to set up in vitro transcription. 2. Embryo Microinjection 1. Inject the nuclease mRNA. Pronuclear stage oocytes are typically injected in the early afternoon. Cytoplasmic mRNA microinjection is carried out in M2 medium under mineral oil using an inverted microscope equipped with Nomarski DIC using 20X objective and with embryo micromanipulators as well as an injection unit. We recommend commencing the injections of TALEN mRNA at a concentration of 10 ng/µl (20 ng/µl in total). 2. Aspirate the oocyte with a holding capillary and inject the nuclease mRNA in the cytoplasm of the embryo avoiding contact with the pronuclei. The injection should be shallow, close to the plasma membrane. The injection volume should be kept low and the microinjection needle should be withdrawn at the first sign of cytoplasmic distension. A microinjection series will normally consist of 100-300 oocytes. Typically, at least 80-90% of the embryos should survive the injection without immediate lysis. 3. Following microinjection, place the embryos for 1 hr in M16 (Sigma) medium at 37 °C and 5% CO 2 and transfer the surviving embryos into pseudopregnant foster mothers.
Surgical Embryo Transfer
1. Prepare pseudopregnant embryo recipients (foster mothers) one day before mRNA microinjection. Mature females (3-6 months old) of a robust outbred strain, such CD-1, are well suited for the role. Induce pseudopregnancy by mating the females on a previous day with either surgically or genetically vasectomized males 28 5. Visualize and externalize the uterine horn by pulling on the fat pad attached to the ovary. Keep the organs moist using warm 0.9% NaCl solution. Keep in mind that the surgical site may have to be draped with sterile dressing or shaved in order to conform to local veterinary guidelines. 6. Immobilize the reproductive organs by clipping the ovary fat pad with a bulldog clamp. 7. Gently grasp the oviduct just upstream of the ampulla with watchmaker forceps and use a 30 G hypodermic needle to create a small hole in the oviduct wall. 8. Withdraw the needle and reinsert a thin glass capillary containing the embryos into the hole allowing the placement of the embryos in the ampulla by gently blowing into the mouthpiece of the capillary holder. Withdraw the capillary once the embryos are deposited in the ampulla and replace the reproductive organs back in the body cavity. 9. Close the peritoneal cavity with a series of sterile sutures (Prolene 6-0). 10. Close the skin using 1-2 wound clips (Autoclip 9 mm) depending on the size of the opening. 11. Following the operation return the animals to their home cage and supervise them until the effect of anesthesia wear off. 12. In order to minimize stress, house the mice in stable social groups (2-4 animals/type III cage) whenever possible. 13. Apply post-operative analgesics in the form of Dafalgan added to the drinking water (Paracetamol 200 mg/kg BW) for 3 days after the surgery.
Analysis of Founders by PCR and T7 Endonuclease or Restriction Enzyme Digestion
1. Design primers to amplify a region between 200-700 bp around the nuclease binding site. The distances forward primer-nuclease spacer region and nuclease spacer region-reverse primer should be sufficiently different to allow detection of two separate bands for digested products on an agarose gel (see Figures 3 and 4 for examples). 2. Run PCR with optimized conditions. Check PCR amplicon size on an agarose gel. 3. Optional: Purify PCR products, e.g. with QIAquick PCR Purification Kit to remove salts and nucleotides from the PCR mix. Many restriction enzymes are active in PCR samples complemented with the appropriate restriction enzyme buffer and purification is not needed. We have also successfully used T7 endonuclease in QiagenTaq PCR buffer complemented with NEBuffer 2. Digest at appropriate temperature for 1 hr or more.
5. Add DNA loading dye to samples and run on a 2% agarose gel to detect distinct digestion patterns for wild-type animals and founders carrying mutated alleles. See Figures 3 and 4 for expected results. 6. Clone PCR products of founders positive for mutated alleles for Sanger sequencing (e.g. by TA-cloning into pGEM-T Easyor directly sequence mixtures of PCR products using next-generation sequencing.
Representative Results
We constructed destination plasmids compatible with the Golden GateTALEN assembly published by Cermak et al. 13 that allow expression of TALENs in mammalian cells as well as in vitro mRNA synthesis from the T7 phage promoter ( Figure 1C) . These plasmids carry heterodimeric FokI domains (ELD or KKR mutations) that have been shown to reduce off-target effects relative to FokI homodimers and to enhance cleavage activity as compared to first generation FokI heterodimers 25, 29 . Golden gate assembly reactions #1 and #2 are usually very efficient and every white colony, when analyzed by colony PCR, shows the expected pattern for the particular number of RVDs cloned (Figures 1B and 1D) .
Gel analysis of in vitro synthesized mRNA (Figure 2) should reveal a single distinguishable band with little or no smear for every sample analyzed. There should be a clear size shift between samples L1/R1 and L2/R2, L3/R3, which indicates successful polyadenylation.
Founder animals can be screened for NHEJ-induced mutated alleles using genotyping PCR followed by either T7 endonuclease digestion (Figure 3) or a restriction digest using an enzyme that cleaves the wild type sequence within the spacer region of the nuclease pair (Figure 4) . The T7 endonuclease assay is applicable to any kind of mutation irrespective of the specific genomic sequence within the spacer region of the nuclease pair injected; however, it detects only mismatches between DNA strands in heteroduplex PCR products. Thus, in the rare event that a founder carries two identically mutated alleles, PCR products would not show any T7 digestion pattern. Such distinction is, however, always possible when a specific restriction site is located within the nuclease spacer region that will be eliminated by NHEJ-induced insertions/deletions ( Figure 5) . Here, undigested bands indicate the presence of mutations, and the absence of any digested products strongly suggests a founder carrying mutations in both alleles of the targeted gene (marked with asterisks in Figure 4b ). 
Discussion
Designer nuclease-driven genome editing approaches have significantly extended the range of species amenable to targeted modifications of their respective genomes 10, 12 . In mice, gene-targeting in ES cells has been a standard technique for over two decades; however, it has proven difficult to adapt to ES cells from species other than the mouse, although there has been some recent success in rat ES cells. Even with the availability of "off-the-shelf" gene-targeted mouse ES cell clones provided by consortia such as EUCOMM, KOMP, or NorCOMM 3 genome editing by ZFN and TALEN provides higher precision and flexibility regarding the spectrum of modifications that can be introduced into the mouse genome. Founder animals carrying nuclease-mediated mutations seem to be highly germ-line competent [4] [5] [6] 20, 21 , which is not always the case for chimeras originating from blastocyst injections of ES cells. Thus, in certain cases microinjection of designer nucleases can result in significantly faster generation of novel mouse lines with targeted genome modifications.
The successful generation of knockout mice by injection of ZFN and TALEN depends to a great extent on the activity of the injected nuclease pair. TALENs have been shown to have a high success rate in targeting a wide range of genes in a number of organisms; however, recent studies suggest that TALEN binding is sensitive to cytosine methylation 30, 31 .Thus, newly generated nuclease pairs, for example TALENs cloned into pCAG-T7 vectors, can be transfected transiently into a mouse cell line such as NIH-3T3 or Neuro-2a, which mimic the chromatin state of the mouse embryo to some extent. Here, nuclease activity can be estimated using the T7 endonuclease assay or a restriction digest of PCR product as described in section 5 prior to mRNA synthesis and microinjection. We recommend sequencing of the genomic region of interest in the respective cell line and the mouse strain used for microinjection experiments.
In mouse zygotes, different TALEN or ZFN pairs will work optimally at different mRNA concentrations and therefore the optimal working concentration of the microinjected nuclease mRNA may have to be determined experimentally. Depending on the nuclease pair, too low a concentration will result in no cleavage whereas too high can result in embryo lethality. Depending on the nuclease pair, we have had success using total mRNA concentrations as low as 2 ng/µl and as high as 200 µg/ul. These effects are difficult to predict from experiments in cell culture and the nuclease concentration optimal for both embryo survival and modification rate of the target locus needs to be determined empirically.
Highly active ZFN or TALEN can cleave their target sequence beyond the one-cell stage of the microinjected embryo and thus cause complex patterns of mutagenesis and mosaicism in founders. We and others 4 have observed three or more distinct mutated alleles in a single founder ( Figure 5C ). Thus, when establishing a new mouse line from these founders, offspring should be carefully screened by sequencing for the presence of the favorable mutation since digestion assays provide evidence only that an undefined mutation is present.
One of the criticisms frequently voiced against the ZFN and TALEN systems is the possibility that these nucleases are also capable of cleaving sequences present somewhere else in the genome that are similar to the target sites. Such off-target effects have been observed with early generation reagents using the homodimeric FokI domain, and heterodimer constructs were designed to alleviate off-target effects 25 . Potential off-target sites can be predicted to some extent in silico 32, 33 and screened by PCR and sequencing. An obvious advantage of using ZFNs and TALENs for generating mice rather than cell lines is the possibility of removing off target mutations unlinked to desired genome modification by performing several backcrosses to a wild-type strain of choice. For the analysis of a large number of founder mice, next-generation deep sequencing of PCR products generated from the nuclease-targeted locus and in silico predicted off-target loci might offer an alternative qualitative and quantitative readout to the digestion assays of PCR products.
The assisted reproductive techniques described in this protocol are optimized for standard mouse strains used for microinjection experiments such as C57Bl/6J or B6D2F1. Mice of different origins, such as outbred strains, can in principle be used for genome editing approaches and might provide a more suitable genetic background for specific research questions. The performance of assisted reproductive techniques such as superovulation can be predicted for a number of strains [34] [35] [36] but might require further optimization for nonstandard strains in order to obtain a sufficient number of embryos for nuclease microinjection.
Besides ZFN and TALEN, new designer nucleases such as the RNA-guided CRISPR/Cas9 system 9,37,38 have now been introduced for genome editing applications. All methods for microinjection and analysis of founder animals described here are also applicable to CRISPR/Cas9 and future modes of genome editing.
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